Table 1 Patient characteristics.
Characteristic | n = 126 | |
|---|---|---|
Age, years, range, (median) | 43–86 | 70.0 |
Sex, N (%) | ||
Male | 91 | 72.2 |
Female | 35 | 27.8 |
Primary site, N (%) | ||
Bladder | 61 | 48.4 |
Upper urinary tract | 62 | 49.2 |
Both | 3 | 2.4 |
Surgical removal of primary site, N (%) | ||
Yes | 78 | 61.9 |
No | 48 | 38.1 |
Chemotherapy regimen, N (%) | ||
Gemcitabine Cisplatin | 77 | 61.1 |
Gemcitabine Nedaplatin | 49 | 38.9 |
Number of chemotherapy cycles, range (median) | ||
Gemcitabine Cisplatin | 1–16 | 4 |
Gemcitabine Nedaplatin | 1–6 | 3 |
ECOG PS, N (%) | ||
0 | 100 | 79.4 |
1 | 24 | 19.0 |
≥ 2 | 2 | 1.6 |
Metastatic sites, N (%) | ||
Lymph nodes only | 34 | 27.0 |
Visceral metastasis (lung, liver, or bone) | 59 | 46.8 |
Local recurrence, other organs | 33 | 26.2 |
MSKCC risk score, N (%) | ||
0 | 53 | 42.1 |
1 | 61 | 48.4 |
2 | 12 | 9.5 |
Hemoglobin (g/dL), N (%) | ||
≥ 10 | 103 | 81.7 |
< 10 | 23 | 18.3 |
eGFR (ml/min/1.73 m2), range, (median) | 7–149 | 50 |
eGFR (ml/min/1.73 m2), N (%) | ||
≥ 50 | 67 | 53.2 |
< 50 | 59 | 46.8 |
Fib-4 index, N (%) | ||
< 3.5 | 122 | 96.8 |
≥ 3.5 | 4 | 3.2 |
ALBI score, N (%) | ||
≤ − 2.6 | 51 | 40.5 |
> − 2.6 | 75 | 59.5 |
NLR, N (%) | ||
< 5.0 | 90 | 71.4 |
≥ 5.0 | 36 | 28.6 |
FAN score, N (%) | ||
0 | 41 | 32.5 |
1 | 56 | 44.4 |
2 | 28 | 22.2 |
3 | 1 | 0.8 |
Treatment after 1st line chemotherapy, N (%) | ||
Immune checkpoint inhibitor | 42 | 33.3 |
Enfortumab vedotin | 5 | 4.0 |
Other chemotherapy | 32 | 25.4 |
Observation period, month, range (median) | 0.5–202.9 | 12.2 |
